TY - JOUR
T1 - Effects of a single dose levodopa on heart rate variability in Parkinson's disease
AU - Meng, Lingqiu
AU - Dunckley, Erika D.
AU - Xu, Xiaolin
PY - 2015/2/17
Y1 - 2015/2/17
N2 - OBJECTIVE: To explore the effects of levodopa on heart rate variability (HRV) in Parkinson's disease (PD).METHODS: A total of 48 PD patients (M:F = 35: 13, mean age: 59 ± 6 years, duration of illness: 4.7 ± 1.8 years, Hoehn & Yahr stage: 2.2 ± 0.3) on a stable dose of levodopa were recruited from January 2012 to May 2014.For confirming autonomic dysfunction, the baseline patient data (12 hours off-medication) were compared with a control group consisting of 48 age and gender-matched healthy subjects (M: F = 35: 13, mean age 58 ± 6 years). Resting lead II electrocardiogram (ECG) was recorded at baseline and continuously after two tablets of 100/10 mg levodopa/carbidopa.However, 5-min segments were selected from every quarter, i.e., Q1 (0-15 min), Q2 (15-30 min), Q3 (30-45 min) and Q4 (45-60 min). Artifact-free 5-min segments of ECG were analyzed offline to acquire the parameters of heart rate variability in time and frequency domains.RESULTS: At baseline, PD patients had a significantly reduced standard deviation of normal-to-normal intervals (SDRR) [(24 ± 4) vs (26 ± 4) ms, P < 0.01)] and total power (TP) [(569 ± 180) vs (652 ± 205) ms², P < 0.05] when compared to controls. Comparing of HRV in PD patients at baseline and during first hour after drug administration, we observed significant increase in SDRR [(29 ± 12) vs (24 ± 8) ms, P < 0.05)], TP [(708 ± 253) vs (569 ± 180) ms², P < 0.01], low frequency power (LF) [(203 ± 98) vs (168 ± 60) ms², P < 0.05) ] and high frequency power (HF) [158 ± 86) vs (114 ± 90) ms², P < 0.05] in Q3.CONCLUSION: The results suggest an improvement in the overall variability of heart rate resulting from an enhanced vagal tone.
AB - OBJECTIVE: To explore the effects of levodopa on heart rate variability (HRV) in Parkinson's disease (PD).METHODS: A total of 48 PD patients (M:F = 35: 13, mean age: 59 ± 6 years, duration of illness: 4.7 ± 1.8 years, Hoehn & Yahr stage: 2.2 ± 0.3) on a stable dose of levodopa were recruited from January 2012 to May 2014.For confirming autonomic dysfunction, the baseline patient data (12 hours off-medication) were compared with a control group consisting of 48 age and gender-matched healthy subjects (M: F = 35: 13, mean age 58 ± 6 years). Resting lead II electrocardiogram (ECG) was recorded at baseline and continuously after two tablets of 100/10 mg levodopa/carbidopa.However, 5-min segments were selected from every quarter, i.e., Q1 (0-15 min), Q2 (15-30 min), Q3 (30-45 min) and Q4 (45-60 min). Artifact-free 5-min segments of ECG were analyzed offline to acquire the parameters of heart rate variability in time and frequency domains.RESULTS: At baseline, PD patients had a significantly reduced standard deviation of normal-to-normal intervals (SDRR) [(24 ± 4) vs (26 ± 4) ms, P < 0.01)] and total power (TP) [(569 ± 180) vs (652 ± 205) ms², P < 0.05] when compared to controls. Comparing of HRV in PD patients at baseline and during first hour after drug administration, we observed significant increase in SDRR [(29 ± 12) vs (24 ± 8) ms, P < 0.05)], TP [(708 ± 253) vs (569 ± 180) ms², P < 0.01], low frequency power (LF) [(203 ± 98) vs (168 ± 60) ms², P < 0.05) ] and high frequency power (HF) [158 ± 86) vs (114 ± 90) ms², P < 0.05] in Q3.CONCLUSION: The results suggest an improvement in the overall variability of heart rate resulting from an enhanced vagal tone.
UR - http://www.scopus.com/inward/record.url?scp=84964695083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964695083&partnerID=8YFLogxK
M3 - Article
C2 - 25916922
AN - SCOPUS:84964695083
SN - 0376-2491
VL - 95
SP - 493
EP - 495
JO - Zhonghua yi xue za zhi
JF - Zhonghua yi xue za zhi
IS - 7
ER -